- Mount Sinai Doctors
- Treats Adults
- Accepting New Patients
Ophir Keret, MD
Neurology
About Me
Dr. Ophir Keret is a behavioral neurologist specializing in young-onset dementias, including Alzheimer's disease, Lewy body and frontotemporal dementia. He also provides inpatient care and emergency neurology settings. He is an assistant Professor of Neurology at the Icahn School of Medicine at Mount Sinai and a faculty member in the Division of Behavioral Neurology at the Mount Sinai Memory and Aging Center.
Dr. Keret's research is focused on developing remote, online and self administered symptom questionnaires for accurate diagnosis of dementia syndromes. His work brings together clinical neurology, data science, and public health, with a strong emphasis on accessibility and equity in dementia care.
Dr. Keret has received multiple awards for clinical excellence and research innovation. He is an active member of the Alzheimer’s Association ISTAART and the International Society for Frontotemporal Dementias, and regularly presents his work at national and international conferences.
Research Interests
Digital phenotyping and symptom clustering in dementia
Early detection of Lewy body dementia and frontotemporal degeneration
Equity in dementia diagnostics and care access
Machine learning and patient-reported outcomes
Professional Affiliations
Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART)
International Society for Frontotemporal Dementias (ISFTD)
Language
English, Hebrew
Position
ASSISTANT PROFESSOR | Neurology
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
Education
MD, University of Debrecen Medical & Health Sciences Center
Internship, Transitional Year
Chaim Sheba Medical Center
Residency, Internal Medicine
Chaim Sheba Medical Center
Residency, Neurology
Rabin Medical Center
Fellowship, Neurodegenerative & Behavioral Neurology
UCSF Medical Center
Fellowship, Behavioral Neurology & Neuropsychiatry
Icahn School of Medicine at Mount Sinai
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
- AETNA - Commercial
- AETNA - Medicare
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Oscar
- VNSNY Choice Medicare
- VNSNY Select Health Medicaid
- VillageCareMax
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Keret did not report having any of the following types of financial relationships with industry and other outside entities during 2024 and/or 2025: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.